Thiazolidinediones News and Research

RSS
Thiazolidinediones are adjunctive therapies for diabetes mellitus (type 2) and related diseases.
New understanding on insulin resistance, action of diabetes drugs may lead to safer medication

New understanding on insulin resistance, action of diabetes drugs may lead to safer medication

American Heart Association comments on FDA advisory committee's rosiglitazone recommendations

American Heart Association comments on FDA advisory committee's rosiglitazone recommendations

Researchers report no increased rate of heart attack in patients taking rosiglitazone

Researchers report no increased rate of heart attack in patients taking rosiglitazone

Welchol plus metformin combination therapy reduces A1C, LDL-C levels in type 2 diabetes patients

Welchol plus metformin combination therapy reduces A1C, LDL-C levels in type 2 diabetes patients

Rosiglitazone associated with increased risk of serious cardiovascular events compared with pioglitazone

Rosiglitazone associated with increased risk of serious cardiovascular events compared with pioglitazone

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx undertakes Phase II clinical trial of CCX140

ONGLYZA-metformin combination: FDA accepts NDA for review

ONGLYZA-metformin combination: FDA accepts NDA for review

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Joint science advisory issues messages for diabetics at risk for heart disease and stroke

Joint science advisory issues messages for diabetics at risk for heart disease and stroke

FDA approves Novo Nordisk's Victoza for type 2 diabetes

FDA approves Novo Nordisk's Victoza for type 2 diabetes

Positive results from study comparing exenatide once weekly to BYETTA

Positive results from study comparing exenatide once weekly to BYETTA

Sulphonylureas, an antidiabetic drug, carries greater risk of heart failure and death compared to metformin

Sulphonylureas, an antidiabetic drug, carries greater risk of heart failure and death compared to metformin

New diabetes algorithm released by AACE for the management of type 2 diabetes

New diabetes algorithm released by AACE for the management of type 2 diabetes

FDA approves Daiichi Sankyo's sNDA for Welchol

FDA approves Daiichi Sankyo's sNDA for Welchol

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: Population-based cohort study

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: Population-based cohort study

NDA for Exenatide once weekly accepted for FDA review

NDA for Exenatide once weekly accepted for FDA review

Discovery of genetic markers to help fight diabetes

Discovery of genetic markers to help fight diabetes